AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7042092 — intervention group
Group type: COMPARATOR
Intervention: IF radiotherapy
Number of subjects: 305
Study 7042092 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 305
Study 31922265 — intervention group
Group type: EXPERIMENTAL
Intervention: Digene Hybrid Capture 2 HPV test with LBC
Number of subjects: 15955
Study 30554882 — intervention group
Group type: EXPERIMENTAL
Intervention: BNO 1030 (Imupret®) as a supplement to standard symptomatic therapy
Number of subjects: 238
Study 30554882 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 238
Study 26575144 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.4 μg/kg bolus followed by 0.2 to 0.7 μg/kg/h infusion)
Number of subjects: 183
Study 26575144 — intervention group
Group type: COMPARATOR
Intervention: Propofol (25 to 50 μg/kg/min infusion)
Number of subjects: 183
Study 25123162 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple courses of antenatal corticosteroids (ACS) therapy
Number of subjects: 1719
Study 25123162 — intervention group
Group type: COMPARATOR
Intervention: Single course of antenatal corticosteroids (ACS) therapy
Number of subjects: 1719
Study 25123162 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age at birth
Number of subjects: 1719
Study 25123162 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between ACS groups and gestational age at birth
Number of subjects: 1719
Study 22757662 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium picosulphate (Picoprep) bowel preparation
Number of subjects: 104
Study 19201016 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of desloratadine
Number of subjects: 30
Study 19201016 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of desloratadine
Number of subjects: 30
Study 19201016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17654322 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-dialytic endurance training on an ergometer three times a week for one year
Number of subjects: 55
Study 16141777 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring-based nursing intervention
Number of subjects: 0
Study 12164403 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlogenzym (bromelain 90 mg, trypsin 48 mg, rutin 100 mg)
Number of subjects: 60
Study 12164403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12164403 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlogenzym
Number of subjects: 60
Study 10442597 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 60
Study 10442597 — intervention group
Group type: COMPARATOR
Intervention: Minimal enteral feeding (3% to 24% of total calorie intake)
Number of subjects: 60
Study 10442597 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (patients not receiving TPN)
Number of subjects: 60
Study 7812574 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol (50 micrograms twice daily)
Number of subjects: 140
Study 7812574 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol (200 micrograms four times a day)
Number of subjects: 140
Study 7812574 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 140
Study 1972797 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms dexmedetomidine (MPV‐1440), a selective alpha 2‐adrenoceptor agonist
Number of subjects: 11
Study 1972797 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg atipamezole (MPV‐1248), a selective alpha 2‐adrenoceptor antagonist
Number of subjects: 11
Study 1972797 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 11
Study 74569 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright group
Number of subjects: 40
Study 74569 — intervention group
Group type: COMPARATOR
Intervention: Recumbent group
Number of subjects: 40
Study 31475470 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with non‐ablative fractional laser and intralesional steroid injection (1550‐nm erbium‐glass fractional laser treatment)
Number of subjects: 38
Study 31475470 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with non‐ablative fractional laser and intralesional steroid injection
Number of subjects: 38
Study 31475470 — intervention group
Group type: COMPARATOR
Intervention: Control group (steroid injection alone)
Number of subjects: 38
Study 29451326 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial breastfeeding
Number of subjects: 69159
Study 29451326 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding
Number of subjects: 69159
Study 29451326 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal intention to breastfeed
Number of subjects: 69159
Study 27303788 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 (≥77.6 mg/m2/day)
Number of subjects: 111
Study 27303788 — intervention group
Group type: COMPARATOR
Intervention: S-1 (≤65.9 mg/m2/day)
Number of subjects: 111
Study 27303788 — intervention group
Group type: EXPERIMENTAL
Intervention: GS (≥65.1 mg/m2/day)
Number of subjects: 111
Study 27303788 — intervention group
Group type: COMPARATOR
Intervention: GS (≤53.8 mg/m2/day)
Number of subjects: 111
Study 27303788 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 (top 10% group)
Number of subjects: 111
Study 27303788 — intervention group
Group type: COMPARATOR
Intervention: S-1 (bottom 10% group)
Number of subjects: 111
Study 27303788 — intervention group
Group type: EXPERIMENTAL
Intervention: GS (top 10% group)
Number of subjects: 111
Study 27303788 — intervention group
Group type: COMPARATOR
Intervention: GS (bottom 10% group)
Number of subjects: 111
Study 24575717 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Imagery (MI)
Number of subjects: 16
Study 24575717 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study 23118932 — intervention group
Group type: EXPERIMENTAL
Intervention: GTP (500 mg daily)
Number of subjects: 171
Study 23118932 — intervention group
Group type: EXPERIMENTAL
Intervention: TC (60-minute group exercise, 3 times/week)
Number of subjects: 171
Study 23118932 — intervention group
Group type: EXPERIMENTAL
Intervention: GTP (500 mg daily) + TC (60-minute group exercise, 3 times/week)
Number of subjects: 171
Study 23118932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 21048953 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant replication-defective adenovirus type 5 (rAd5) vaccine expressing HIV-1 Gag, Pol, and multiclade Env proteins, VRC-HIVADV014-00-VP, at a dose of 10^10 or 10^11 adenovector particle units
Number of subjects: 87
Study 21048953 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant replication-defective adenovirus type 5 (rAd5) vaccine
Number of subjects: 87
Study 16956709 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacid-modified resin composite/resin composite open sandwich technique
Number of subjects: 57
Study 16956709 — intervention group
Group type: COMPARATOR
Intervention: Direct resin composite restoration
Number of subjects: 57
Study 16956709 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 57
Study 15969949 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapidly disintegrating stanol lecithin tablets (1.26 g stanols daily)
Number of subjects: 52
Study 15969949 — intervention group
Group type: EXPERIMENTAL
Intervention: Slowly disintegrating capsules (1.01 g daily)
Number of subjects: 52
Study 15969949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 12324640 — intervention group
Group type: EXPERIMENTAL
Intervention: Polynutrient supplement (twice daily for 10 weeks)
Number of subjects: 53
Study 12324640 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily for 10 weeks)
Number of subjects: 53
Study 10027431 — intervention group
Group type: EXPERIMENTAL
Intervention: Infused Ang II at 1 ng/kg/min
Number of subjects: 8
Study 10027431 — intervention group
Group type: EXPERIMENTAL
Intervention: Infused Ang II at 2 ng/kg/min
Number of subjects: 8
Study 10027431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10027431 — intervention group
Group type: EXPERIMENTAL
Intervention: Infused Ang II at 1 ng/kg/min and 2 ng/kg/min
Number of subjects: 8
Study 8643170 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose iron therapy (100 mg at the end of HD treatment)
Number of subjects: 64
Study 8643170 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose iron therapy (10, 20, or 40 mg per HD depending on haemoglobin, serum ferritin, and transferrin saturation)
Number of subjects: 64
Study 8643170 — intervention group
Group type: COMPARATOR
Intervention: Intravenous rHuEpo therapy
Number of subjects: 64
Study 8643170 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous rHuEpo therapy
Number of subjects: 64
Study 8643170 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of iron administration
Number of subjects: 64
Study 8643170 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEpo therapy in well-nourished patients (serum albumin > 40 g/l) without hyperparathyroidism
Number of subjects: 64
Study 8643170 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEpo therapy in patients with hyperparathyroidism
Number of subjects: 64
Study 2298365 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin administration
Number of subjects: 0
Study 2298365 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 0
Study 2298365 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 0
Study 7014392 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation
Number of subjects: 136
Study 7014392 — intervention group
Group type: COMPARATOR
Intervention: No additional therapy (control)
Number of subjects: 136
Study 27762041 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute free-weight resistance exercise (ARE)
Number of subjects: 15
Study 27762041 — intervention group
Group type: COMPARATOR
Intervention: Quiet control (CON)
Number of subjects: 15
Study 27406639 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal integrative medicine education programme plus standard care
Number of subjects: 176
Study 27406639 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 176
Study 23432666 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified polylactide/polyglycolide acid (PLGA) test membrane
Number of subjects: 40
Study 23432666 — intervention group
Group type: COMPARATOR
Intervention: Expanded polytetrafluorethylene (ePTFE) control membrane
Number of subjects: 40
Study 23432666 — intervention group
Group type: EXPERIMENTAL
Intervention: Both membranes
Number of subjects: 40
Study 22143925 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular injection of gadopentetate dimeglumine, ropivacaine 0.5%, and normal saline (group A)
Number of subjects: 127
Study 22143925 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular injection of gadopentetate dimeglumine and normal saline (group B)
Number of subjects: 127
Study 20167989 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines plus CHD risk profiles
Number of subjects: 3266
Study 20167989 — intervention group
Group type: COMPARATOR
Intervention: Guidelines alone
Number of subjects: 3266
Study 18765509 — intervention group
Group type: EXPERIMENTAL
Intervention: Asoprisnil 10 mg
Number of subjects: 33
Study 18765509 — intervention group
Group type: EXPERIMENTAL
Intervention: Asoprisnil 25 mg
Number of subjects: 33
Study 18765509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 16126397 — intervention group
Group type: EXPERIMENTAL
Intervention: Superiorly based masseter muscle flap
Number of subjects: 22
Study 16126397 — intervention group
Group type: EXPERIMENTAL
Intervention: Island masseter muscle flap
Number of subjects: 22
Study 14652471 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear-avoidance-based physical therapy (n = 34)
Number of subjects: 66
Study 14652471 — intervention group
Group type: COMPARATOR
Intervention: Standard care physical therapy (n = 32)
Number of subjects: 66
Study 11126105 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8866803 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-valent pneumococcal conjugate vaccine (3 doses of 5 micrograms of types 6B, 14, 18, 19F, and 23F polysaccharides conjugated to CRM197)
Number of subjects: 90
Study 8866803 — intervention group
Group type: COMPARATOR
Intervention: H. influenzae type b vaccine (2 doses)
Number of subjects: 90
Study 1632567 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (12.5 to 50 mg three times a day)
Number of subjects: 12
Study 1632567 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (20 to 160 mg once a day)
Number of subjects: 12
Study 1632567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6436700 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide (1 mg subcutaneously daily)
Number of subjects: 199
Study 6436700 — intervention group
Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES, 3 mg by mouth daily)
Number of subjects: 199
Study 30306884 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole (conversion over 22-33 days)
Number of subjects: 404
Study 30306884 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole (conversion over 1-7 days)
Number of subjects: 404
Study 30306884 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole (conversion over 8-14 days)
Number of subjects: 404
Study 30306884 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole (conversion over 15-21 days)
Number of subjects: 404
Study 30306884 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole (all conversion groups)
Number of subjects: 404
Study 29980460 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound
Number of subjects: 120
Study 29980460 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study 26556391 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible knee support (brace)
Number of subjects: 108
Study 26556391 — intervention group
Group type: COMPARATOR
Intervention: No brace (control)
Number of subjects: 108
Study 24633138 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccadic eye movement training with visual scanning exercises (VSEs) integrated with task-specific activities
Number of subjects: 24
Study 24633138 — intervention group
Group type: COMPARATOR
Intervention: Control group (task-specific activities only)
Number of subjects: 24
Study 22395644 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen monotherapy
Number of subjects: 4861
Study 22395644 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 4861
Study 20083693 — intervention group
Group type: EXPERIMENTAL
Intervention: pimecrolimus, 1%, cream
Number of subjects: 3
Study 18274206 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine (12g mixed in 113g applesauce)
Number of subjects: 85
Study 18274206 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined levothyroxine (50 microg) and liothyronine (12.5 microg) supplement
Number of subjects: 85
Study 18274206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 15857745 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids for symptom palliation in intestinal obstruction
Number of subjects: 29
Study 15857745 — intervention group
Group type: COMPARATOR
Intervention: Normal adrenal function (Group 1)
Number of subjects: 29
Study 15857745 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenal insufficiency (Group 2)
Number of subjects: 29
Study 12172280 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiglide plating
Number of subjects: 193
Study 12172280 — intervention group
Group type: COMPARATOR
Intervention: Lateral plating
Number of subjects: 193
Study 9539578 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial thermometry during hyperthermia treatment
Number of subjects: 215
Study 9539578 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial thermometry
Number of subjects: 215
Study 7595819 — intervention group
Group type: EXPERIMENTAL
Intervention: Information and coping skills training
Number of subjects: 48
Study 7595819 — intervention group
Group type: COMPARATOR
Intervention: Routine information provision (Control)
Number of subjects: 48
Study 2695860 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy with adjuvant Glipressina
Number of subjects: 20
Study 2695860 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy without adjuvant Glipressina
Number of subjects: 20
Study 1275989 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (1.25-10 mug/kg per min)
Number of subjects: 11
Study 1275989 — intervention group
Group type: COMPARATOR
Intervention: Isoprenaline (0.005-0.04 mug/kg per min)
Number of subjects: 11
Study 31335198 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-led titration of insulin glargine 100 U/mL
Number of subjects: 75
Study 31335198 — intervention group
Group type: COMPARATOR
Intervention: Physician-led titration of insulin glargine 100 U/mL
Number of subjects: 75
Study 31335198 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 75
Study 28538261 — intervention group
Group type: EXPERIMENTAL
Intervention: Better Exercise Adherence after Treatment for Cancer (BEAT Cancer)
Number of subjects: 222
Study 28538261 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 222
Study 26541350 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid group (0.5 mg/kg intravenous methylprednisolone for 2 days followed by 12 mg daily oral methylprednisolone for 4 days)
Number of subjects: 138
Study 26541350 — intervention group
Group type: COMPARATOR
Intervention: Control group (no steroid therapy)
Number of subjects: 138
Study 26541350 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid group
Number of subjects: 138
Study 26541350 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 138
Study 23151649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy (RT)
Number of subjects: 125
Study 17109580 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic capsules containing Lactobacillus acidophilus and Bifidobacterium longum
Number of subjects: 31
Study 17109580 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 31
Study 15193361 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) levels of pigment epithelium-derived factor (PEDF)
Number of subjects: 0
Study 15193361 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) levels of PEDF
Number of subjects: 0
Study 10939775 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic treatment
Number of subjects: 2400
Study 10939775 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 2400
Study 10939775 — intervention group
Group type: COMPARATOR
Intervention: Homeopathic or conventional treatment according to patient preference
Number of subjects: 2400
Study 8622602 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (ACX) 500 mg (one dose)
Number of subjects: 13
Study 8622602 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (ACX) for 1 month
Number of subjects: 13
Study 8622602 — intervention group
Group type: COMPARATOR
Intervention: GHRH (1-29) 1 microg/kg IV
Number of subjects: 13
Study 8622602 — intervention group
Group type: COMPARATOR
Intervention: Baseline FFA levels
Number of subjects: 13
Study 8622602 — intervention group
Group type: EXPERIMENTAL
Intervention: One-dose ACX (500 mg)
Number of subjects: 13
Study 1533478 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-derived vaccine (Green Cross HB-vaccine)
Number of subjects: 58
Study 1533478 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast-derived recombinant vaccine (Engerix B)
Number of subjects: 58
Study 1533478 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of plasma-derived and yeast-derived vaccines
Number of subjects: 58
Study 3967053 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch
Number of subjects: 38
Study 3967053 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen
Number of subjects: 38
Study 3967053 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study 31071612 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Controlled (SC) feedback
Number of subjects: 42
Study 31071612 — intervention group
Group type: COMPARATOR
Intervention: Yoked (YK) feedback
Number of subjects: 42
Study 28366818 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive photodynamic therapy (PDT) with scaling and root debridement
Number of subjects: 27
Study 28366818 — intervention group
Group type: COMPARATOR
Intervention: Control (scaling and root debridement alone)
Number of subjects: 27
Study 28366818 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive photodynamic therapy (PDT)
Number of subjects: 27
Study 26234986 — intervention group
Group type: EXPERIMENTAL
Intervention: High anxiety levels (47.8%)
Number of subjects: 395
Study 26234986 — intervention group
Group type: EXPERIMENTAL
Intervention: High depression levels (38.2%)
Number of subjects: 395
Study 26234986 — intervention group
Group type: EXPERIMENTAL
Intervention: Family status, educational level, number of children, adherence to doctors' orders, proposed diet, relations with healthcare professionals and other patients
Number of subjects: 395
Study 23665342 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU of vitamin D3 per day (low dose)
Number of subjects: 40
Study 23665342 — intervention group
Group type: EXPERIMENTAL
Intervention: 4,370 IU of vitamin D3 per day (high dose)
Number of subjects: 40
Study 21204680 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD+G (computer-assisted dieting plus self-management training)
Number of subjects: 55
Study 21204680 — intervention group
Group type: COMPARATOR
Intervention: CAD-only (computer-assisted dieting only)
Number of subjects: 55
Study 19643917 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical fMRI overt language design with semantic and syntactic error‐detection tasks
Number of subjects: 30
Study 19681255 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide whitening strips (Crest Whitestrips)
Number of subjects: 72
Study 19681255 — intervention group
Group type: EXPERIMENTAL
Intervention: 19% sodium percarbonate brush-applied gel (Crest Night Effects)
Number of subjects: 72